Johan Erik Simon FREDRIKSSON,Olof Andries BLOKZIJL
申请号：
US16477389
公开号：
US20190343962A1
申请日:
2018.01.12
申请国别(地区):
US
年份:
2019
代理人:
摘要：
A therapeutic agent capable of binding to the receptor CLPTM1 at the surface of an immune cell and modulating its activity for use in modulating the activity of the immune system to treat cancer, wherein the therapeutic agent is capable of inhibiting the growth and/or viability of an anti-inflammatory and/or immunosuppressive cell to relieve unwanted or deleterious immunosuppression by eliminating anti-inflammatory and/or immunosuppressive immune cells； and/or the therapeutic agent is capable of stimulating an antigen-presenting immune cell and acts to stimulate antigen-presenting immune cells to activate an anti-cancer immune response.
